前收市價 | 1.6200 |
開市 | 1.6200 |
買盤 | 0.0000 |
賣出價 | 3.1000 |
拍板 | 185.00 |
到期日 | 2026-01-16 |
今日波幅 | 1.6200 - 1.6200 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 2 |
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
美國製藥大廠 Merck(默沙東 / 默克) 周三 (29 日) 同意以高達 30 億美元的價格收購民間生物技術公司 EyeBio,這是 Merck 為促進未來營運成長而進行一連串交易中的最新一筆。這筆交易將於今年第三季完成。
Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.